Information Provided By:
Fly News Breaks for November 29, 2016
NVLS
Nov 29, 2016 | 07:53 EDT
As previously reported, Baird analyst Brian Skorney downgraded Nivalis Therapeutics to Neutral from Outperform following the clinical trial failure of its flagship proof-of-concept study of its drug for cystic fibrosis. Skorney lowered his price target to $3 from $29 on Nivalis Therapeutics shares. Nivalis shares have also been downgraded by at least three other firms this morning.
News For NVLS From the Last 2 Days
There are no results for your query NVLS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.